As laboratory technologies advance, companies are increasingly using bioinformatic analytical software to capture, analyze, annotate, and store data, and most importantly, extract meaningful biological information from it. Drug development companies are using these software tools to increase the efficiency of their processes from hit-finding to clinical trial management. Academic researchers are also generating greater depth and breadth to their research results with these tools. The goals of personalized medicine, the search for more efficacious drugs, and the need for quicker time-to-market are driving growth in this market.

I.Executive SummaryI

A.Bioinformatics Analytical Software OverviewI

B.BackgroundI

C. DefinitionI

D.Historical PerspectiveI

E.ScopeI

F.End User AnalysisI

1.ScopeI

2.Market PerceptionsI

G.Worldwide MarketI

1.Annual Worldwide Revenues (2004E to 2009E)

2.Market Share by Technology Segment (2004E and 2009E)

3.Segment Market GrowthI

4.Supplier Market Share (2004E and 2009E)

H.Trends, Challenges, and Strategic OptionsI

1.TrendsI

2.ChallengesI

3.Strategic OptionsI

II. Objectives and MethodologyII

A. Report Objectives and ScopeII

1.ObjectivesII

2.ScopeII

B.MethodologyII

1.Bioinformatics Analytical Software Market ModelII

2.Model AssumptionsII

C.Key Players and Strategic AnalysisII

1.Technology AssessmentII

2.Market PositionII

3.Comparison ParametersII

a.Sample Player ComparisonII

b.Sample Positioning MatrixII

D.Data CollectionII

1. Primary SourcesII

a. Bioinformatics Analytical Software Industry Thought LeadersII

b.Representative QuestionsII

2.Secondary SourcesII

E.Trends, Challenges, and Strategic OptionsII

1.OverviewII

2.External AnalysisII

III.Technical OverviewIII

A.Bioinformatics OverviewIII

1.BackgroundIII

2.DefinitionIII

3. Historical PerspectiveIII

4.Scientific Background

a.High-throughput Sequencing TechnologiesIII

b.Microarray TechnologiesIII

c.Protein SeparationIII

d.Protein CharacterizationIII

5.Industry LandscapeIII

a.Technology Adoption RateIII

b.Complexity of Bioinformatics ToolsIII

B.SegmentationIII

1.OverviewIII

2.GenomicsIII

a.Case Study: Informax-Vector NTI Advance 9.0III

b.Case Study: Rosetta -RosettaResolverSystemIII

3.CheminformaticsIII

a.Case Study: Tripos -ChemSpaceIII

b.Case Study: Accelrys -CheminformaticsSoftwareIII

4.ProteomicsIII

a.Case Study: Ciphergen  -ProteinChipSoftwareIII

b.Case Study: Scimagix -ProteinMineIII

5.PharmacogenomicsIII

a.Case Study: Genaisasnce -DecoGenInformatics SystemIII

b.Case Study: Applied Biosystems -SeqScapeand Gene MapperSoftwareIII

IV.Bioinformatics Analytical Software MarketIV

A.Worldwide Market

1.Annual Worldwide Revenues (2004E to 2009E)

2.Market Share by Technology Segment (2004E and 2009E)

3.Segment Market Growth

4.Supplier Market Share (2004E and 2009E)

5.Supplier Positional Evaluation AnalysisIV

a.Competitive Matrix Analysis (2004E)

b.Competitive Matrix Analysis (2009E)

B.Market Model ConstructionIV

C.Company ProfilesIV

1.Accelrys, Inc. (A Subsidiary of Pharmacopeia, Inc.)

2.Affymetrix, Inc.

3.AmershamBiosciences, Inc.

4.Applied Biosystems, Inc.

5.DNAStar, Inc.

6.GeneBioSAIV

7.Informax, InvitrogenLife Science SoftwareIV

8.LION Bioscience AGIV

9.MDL Information Systems, Inc.

10.Rosetta BiosoftwareIV

11.SequenomIV

12.Silicon GeneticsIV

13.Spotfire, Inc.

14.Tripos, Inc.

V.End User AnalysisV

A.OverviewV

1.Demographic Distribution of End Users for the StudyV

2. ScopeV

B.Study ResultsV

1.ProductsV

a.Leading ProductsV

b.Product Purchase Decision FactorsV

c.Product Satisfaction LevelV

d.Value AssessmentV

2.SegmentsV

a.Leading IssuesV

b.In-House Development vs. OutsourcingV

3.Future ExpectationsV

a.Growth ExpectationsV

b.Market PerceptionsV

VI.Trends, Challenges, and Strategic OptionsVI

A.OverviewVI

B.TrendsVI

1.OverviewVI

2. Government ComplianceVI

3.Industry-wide TurmoilVI

4.Focus Shifts from Genomics to ProteomicsVI

C.ChallengesVI

1.OverviewVI

2.Lack of Interoperability and Multiplatform CapabilitiesVI

3.Lack of Standardization of FormatsVI

4.Difficult Integration of ApplicationsVI

5.High Volume Data ManagementVI

6.Growing Competition from In-house Development and Publicly Available ToolsVI

D.Strategic OptionsVI

1.OverviewVI

2.Extend Applications Based on Core Technical ExpertiseVI

3.Provide Web-based Services and Value-line ProductsVI

4.Collaborate with Wet-laboratory CompaniesVI

a.Enter the Drug Discovery SpaceVI

b.Enter the Life Sciences Tools SpaceVI

Appendix:

A.DefinitionsA

B.AcronymsA

C. CompaniesA

D.Market ModelA